期刊文献+

A novel polymer-free dual-drug eluting stent with nanotechonology

A novel polymer-free dual-drug eluting stent with nanotechonology
原文传递
导出
摘要 Durable polymers used for first-generation drug-eluting stents potentially contribute to persistent inflammation and late stent thrombosis. BICARE (Lepu Medical Technology Co., Ltd, Beijing, China) is a novel polymer-free stent system with nanotechnology and elutes rapamycin (1.6 μg/mm2) and probucol (0.8 μg/mm2). The millpores on the surface of the stents were produced by nanotechnology. Studies on in-vitro release profile and the preliminary feasibility and safety of the BICARE stent were conducted. The results of release profile study demonstrated the ability of dual-drug polymer-free loading stents to release rapamycin and probucol in a controlled and sustained manner. The preliminary feasibility and safety of BICARE dual-drug polymer-free stent are demonstrated firstly in human study. Optical coherence tomography (OCT) findings indicated excellent stent strut coverage at 4-month. Further pivotal randomized trial will confirm if this early results could translate into longer term safety and efficacy benefits. Durable polymers used for first-generation drug-eluting stents potentially contribute to persistent inflammation and late stent thrombosis. BICARE (Lepu Medical Technology Co., Ltd, Beijing, China) is a novel polymer-free stent system with nanotechnology and elutes rapamycin (1.6 μg/mm2) and probucol (0.8 μg/mm2). The millpores on the surface of the stents were produced by nanotechnology. Studies on in-vitro release profile and the preliminary feasibility and safety of the BICARE stent were conducted. The results of release profile study demonstrated the ability of dual-drug polymer-free loading stents to release rapamycin and probucol in a controlled and sustained manner. The preliminary feasibility and safety of BICARE dual-drug polymer-free stent are demonstrated firstly in human study. Optical coherence tomography (OCT) findings indicated excellent stent strut coverage at 4-month. Further pivotal randomized trial will confirm if this early results could translate into longer term safety and efficacy benefits.
出处 《South China Journal of Cardiology》 CAS 2013年第3期204-210,共7页 岭南心血管病杂志(英文版)
关键词 NANOTECHNOLOGY drug eluting stents polymer-free human trial nanotechnology drug eluting stents polymer-free human trial
  • 相关文献

参考文献13

  • 1Stone GW, Moses JW, Ellis SG, et al. Safety and effi?cacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356:998-1008.
  • 2Holmes Jr DR, Kereiakes DJ, Garg S, el al. Stent thrombosis. J Am Coli Cardiol 2010, 56: 1357-1365.
  • 3Stettler C, Wandel S, Allemann S, et al. Outcomes as?sociated with drug-eluting and bare-metal stents, a col?laborative network meta-analysis. Lancet 2007, 370: 937-948.
  • 4Kogias JS, Papadakis EX, Tsatiris CG, et al. Kounis syndrome: a manifestation of drug-eluting stent throm?bosis associated with allergic reaction to contrast materi- al. Int J Cardiol2010, 139:206-209.
  • 5Kirtane AJ, Gupta A, Iyengar S, et al. Safety and effi?cacy of drug-eluting and bare metal stents , comprehen?sive meta-analysis of randomized trials and observational studies. Circulation 2009, 119: 3198-3206.
  • 6Mauri L, Hsieh WH, Massaro JM, at al. Stent thrombo?sis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356: 1020-1029.
  • 7Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293 : 2126-2130.
  • 8Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
  • 9Joner M, Finn A V, Farb A, et al. Pathology of drug-e?luting stents in humans: delayed healing and late throm?botic risk. J Am Coli Cardiol 2006, 48: 193-202.
  • 10Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. Eur Interv 2010, 6:447-453.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部